目前我能找到的只是说在接受癌症化疗或其他免疫抑制治疗的患者中，观察到体液或细胞免疫疫苗反应降低，最常见于多发性骨髓瘤或其他B细胞恶性肿瘤患者以及接受B细胞治疗或细胞治疗的患者。（Reduced humoral or cellular immune vaccine responses have been observed in patients receiving cancer chemotherapy or other immunosuppressive treatments, most notably in patients with multiple myeloma or other B-cell malignancies and in those receiving B-cell-depleting or cellular therapies.）更多的是白血病潜伏期接种了疫苗而不是疫苗导致了白血病。当然老哥那如果有完整的疫苗和白血病的因果论证，欢迎讨论。
Fendler, A., de Vries, E.G.E., GeurtsvanKessel, C.H. et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol 19, 385–401 (2022). https://doi.org/10.1038/s41571-022-00610-8
Kuderer, N. M., & Lyman, G. H. (2022). COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties. The Lancet. Oncology, 23(6), 693–695. https://doi.org/10.1016/S1470-2045(22)00252-2
目前我能找到的只是说在接受癌症化疗或其他免疫抑制治疗的患者中，观察到体液或细胞免疫疫苗反应降低，最常见于多发性骨髓瘤或其他B细胞恶性肿瘤患者以及接受B细胞治疗或细胞治疗的患者。（Reduced humoral or cellular immune vaccine responses have been observed in patients receiving cancer chemotherapy or other immunosuppressive treatments, most notably in patients with multiple myeloma or other B-cell malignancies and in those receiving B-cell-depleting or cellular therapies.）更多的是白血病潜伏期接种了疫苗而不是疫苗导致了白血病。当然老哥那如果有完整的疫苗和白血病的因果论证，欢迎讨论。
Fendler, A., de Vries, E.G.E., GeurtsvanKessel, C.H. et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol 19, 385–401 (2022). https://doi.org/10.1038/s41571-022-00610-8
Kuderer, N. M., & Lyman, G. H. (2022). COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties. The Lancet. Oncology, 23(6), 693–695. https://doi.org/10.1016/S1470-2045(22)00252-2
